# Thalidomide and Dacarbazine for Metastatic Melanoma

> **NCT00006200** · PHASE2 · UNKNOWN · sponsor: **National Center for Research Resources (NCRR)**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** thalidomide
- **DRUG:** dacarbazine

## Key facts

- **NCT ID:** NCT00006200
- **Lead sponsor:** National Center for Research Resources (NCRR)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006200, "Thalidomide and Dacarbazine for Metastatic Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00006200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*